Objective: To investigate short-term case fatality and long-term mortality after intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH) using data from The Health Improvement Network database.
Hemorrhagic stroke constitutes approximately 10% to 20% of all strokes. 1 The subtypesprimary intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH)-have a worldwide incidence of 24.6 and 9.1 per 100,000 person-years, respectively. 2, 3 Mortality risk is highest in the first weeks after hemorrhagic stroke, and the overall case fatality at 1 month has been reported to be approximately 40% for ICH and 30% for SAH. [2] [3] [4] Individuals who survive the initial 30 days after a hemorrhagic stroke continue to have an increased risk of death compared with members of the general population. [5] [6] [7] [8] However, few published studies have described the secular trends in 30-day case fatality for ICH and SAH, and those that do are limited in size or have inconsistent results. 3, 9, 10 This may reflect the difficulty in obtaining accurate and complete medical records for a sufficient number of patients to enable reliable assessment of diagnoses and their outcomes.
The Health Improvement Network (THIN) is a large UK patient database including data recorded by primary care physicians (PCPs) from as early as 1987 (data were collected prospectively from 2002). THIN has been shown to contain information on a large cohort of patients with hemorrhagic stroke 11 and has the potential to provide important insights into the short-term and longerterm mortality associated with hemorrhagic stroke in the United Kingdom.
In this study, we investigated the 30-day case fatality in patients following ICH or SAH over the period 2000 to 2008 using data from THIN. Mortality during the first year of follow-up and among survivors after 1 year was also compared with the general population.
METHODS Data source. THIN contains longitudinal medical records entered by PCPs from more than 500 general practices across the United Kingdom using Vision computer software. Data from more than 4 million patients on demographics, details of PCP visits, diagnoses by specialists following referrals and hospital admissions, results of laboratory tests, diagnoses, and prescriptions, as well as free text comments are recorded systematically and sent to the database anonymously for use in research projects. THIN has been validated for use in pharmacoepidemiologic research 12 and is known to be representative of the UK population in measures of demographics, chronic disease prevalence, and mortality. 13 Standard protocol approvals, registrations, and patient consents. The collection of data into THIN was approved by the South-East Multicentre Research Ethics Committee in the United Kingdom.
Study cohort. Patients with data in THIN who were aged 20 to 89 years between January 2000 and December 2008 were included in the study cohort on the first day of the study period when they met the following criteria: they had been enrolled with the PCP for at least 2 years; at least 1 year had elapsed since their first computerized prescription; and at least one encounter with the PCP had been recorded in the previous 2 years. Patients were excluded from the study if they had a diagnosis of ICH or SAH before their start date or if they were aged 70 years or older at the start date and were observed for more than 1 year but had no data recorded.
Case and comparison group ascertainment. Follow-up of each patient continued until ICH, SAH, or death was recorded, the individual reached 90 years of age, or the study period ended (December 2008). The method used for detecting hemorrhagic stroke within THIN has been validated and described elsewhere. 11 Traumatic cases of ICH/SAH were excluded.
To evaluate risk factors for hemorrhagic stroke, a case-control study was performed that was nested in a study cohort. 14 Briefly, all cases of hemorrhagic stroke were included in this analysis, using the date of diagnosis as the index date. A group of 10,000 controls within THIN was randomly selected from the pool of eligible persontime (i.e., using density-based sampling) and was frequency matched to all cases of hemorrhagic stroke on sex, age (61 year), and calendar year of diagnosis. The date of selection was used as the index date for control individuals.
For all cases and controls, data on demographic (age, sex, and body mass index) and lifestyle (e.g., smoking and alcohol intake) factors were collected, as well as information on general comorbidities (e.g., chronic conditions and cardiovascular risk factors) at the index date.
Mortality analysis. For the present study, a total of 3,036 individuals (1,733 ICH and 1,303 SAH) with available follow-up data after the event were identified in the nested case-control analysis. The vital status of each patient after the stroke event was ascertained and logistic regression analysis was used to model the temporal trends of 30-day case fatality for hemorrhagic stroke, with adjustment for age and sex. Analyses for men and women were conducted separately and tested for age by study year interactions.
Cox proportional hazards regression analyses were used to determine whether patients were at increased risk of death in the first year (excluding the first 30 days immediately after the event) and after 1 year following ICH or SAH (up until December 2010) compared with the general population in THIN. Available follow-up data from the group of control patients (n 5 9,583) identified in the nested case-control analysis and free of hemorrhagic stroke at the index date were used to estimate survival in the general population in THIN. Hazard ratios (HRs) with 95% confidence intervals (CIs) for risk of death associated with ICH and SAH were calculated. The fully adjusted regression model included frequency-matched variables (i.e., age, sex, and calendar year) and the following covariates: smoking, alcohol intake, body mass index, hypertension, and health services utilization in the year before the index date (PCP visits, referrals, and hospitalizations) (tables e-1-e-3 on the Neurology ® Web site at www.neurology.org).
Conditional on survival 30 days after ICH or SAH, adjusted mortality rates with corresponding 95% CIs for all-cause death were calculated using direct standardization. Age-and sex-specific estimates were also obtained (table e-4). A Cox proportional hazards model was used to calculate age-stratified hazard ratios between patients with ICH, SAH, and the reference population.
All analyses were performed using Stata SE 10.0 (StataCorp, College Station, TX). Overall, the 30-day case fatality for hemorrhagic stroke in this population was 36.3%. Patients with ICH had a higher short-term case fatality than those with SAH (42.0% and 28.7%, respectively) (table 1). This difference was not significant after adjustment for age, sex, and calendar year (p 5 0.08) and it was borderline significant in patients aged 20 to 49 years (p 5 0.05).
For both ICH and SAH, the 30-day case fatality increased with age (ICH, p-trend , 0.001; SAH, p-trend , 0.001), peaking in the 80-89 years age group (tables e-5 and e-6). In the 20-49 years age range, 30-day case fatality for men with ICH was almost 2-fold that for women (figure 1A; p 5 0.02). In contrast, 30-day case fatality for SAH was similar for men and women until the eighth decade, when it reached a plateau for men, but continued to increase for women, even though this increase was not statistically significant (figure 1B; p 5 0.10).
For ICH, 30-day case fatality increased with age in both men and women (increasing from 37.3% in men and 18.9% in women aged 20-49 years to 51.4% in men and 56.8% in women aged 80-89 years) ( figure 1A ; p , 0.001 in both men and women). The 30-day case fatality for SAH increased from 19.5% in men and 20.9% in women aged 20-49 years to 46.9% in men and 62.1% in women aged 80-89 years ( figure 1B ; p , 0.001 in both men and women).
Between 2000-2001 and 2006-2008, a reduction in 30-day case fatality was observed for both men and women with ICH and SAH (tables e-5 and e-6), and across most age groups (table 1 and figure 2). These temporal trends were statistically significant after adjustment for age and sex (ICH, p-trend , 0.001; SAH, p-trend 5 0.02). The largest reduction in case fatality was seen in patients aged Excess mortality in patients within 1 year of hemorrhagic stroke. A total of 1,004 patients with ICH, 929 individuals with SAH, and 9,583 controls were available for follow-up until the end of 2010 (table 2) . Follow-up for individuals in the control group started on the index date. Follow-up in the hemorrhagic stroke cohort began 30 days after the index date, therefore excluding individuals who died within 30 days of the episode. An additional case of ICH lost to follow-up during the 30-day period after the event was also excluded.
Survivors of ICH and SAH had a significantly increased risk of death compared with the control population during the first year of follow-up. Excess mortality within 1 year of the initial event was similar for ICH and SAH (ICH: HR 2.60, 95% CI 2.09-3.24, p , 0.01; SAH: HR 2.87, 95% CI 2.07-3.97, p , 0.01). Overall and age-specific survival curves up to 1 year after hemorrhagic stroke are presented in figures e-1 and e-2.
Figure 1
Thirty-day case fatality after stroke, stratified by sex Thirty-day case fatality for intracerebral hemorrhage (A) and subarachnoid hemorrhage (B) as a proportion of fatal cases among hemorrhagic stroke cases in each stratum.
Excess mortality in patients 1 year after hemorrhagic stroke.
The risk of death remained increased 1 year after the index date among survivors of hemorrhagic stroke compared with the control cohort (ICH: HR 2.02, 95% CI 1.75-2.32, p , 0.01; SAH: HR 1.32, 95% CI 1.02-1.69, p 5 0.03). There was no significant difference in excess mortality between men and women. Overall and age-specific survival curves beyond 1 year after hemorrhagic stroke are presented in figures e-3 and e-4.
Overall excess mortality after hemorrhagic stroke. The HR for overall mortality was 2.19 (95% CI 1.95-2.46, p , 0.01) for ICH and 1.70 (95% CI 1.40-2.07, p , 0.01) for SAH. There was no significant difference in excess mortality between men and women. The overall increased risk of death compared with individuals in the control cohort was observed across all age groups; the excess mortality was greatest for patients who had survived an ICH and were in the age range 20-49 years (HR 14.61, 95% CI 4.48-47.58, p , 0.01; figure 3 ; p-interaction , 0.01). Overall and agespecific survival curves after hemorrhagic stroke are presented in figures e-5 and e-6.
DISCUSSION Few studies have investigated the 30-day case fatality and long-term risk of death after ICH or SAH in the United Kingdom. In this study, analysis of data from more than 3,000 patients with hemorrhagic stroke has shown that more than one-third of individuals die within 30 days of the initial event, and, in those who survive, the risk of death remains significantly increased even 1 year after the stroke compared with the general population.
Overall, 30-day case fatality was higher for patients with ICH than for those with SAH (42.0% and 28.7%, respectively), although this result was not statistically significant after adjustment for age, sex, and calendar year (p 5 0.08). This was consistent with the findings of a systematic review published in 2009, where the mean short-term case fatality (21 days to 1 month) was 41% for ICH and 30% for SAH during the period 2000-2008. 4 The higher case fatality in individuals after ICH compared with SAH can be explained, in part, by differences in the demographics between the 2 patient groups. Individuals diagnosed with ICH were more likely to be older than those diagnosed with SAH (mean age at diagnosis: 70.8 years vs 57.7 years); indeed, when case fatality was compared within age strata, the differences in case fatality between the ICH and SAH groups became more moderate (table 1) .
For patients with SAH, 30-day case fatality increased steeply with age, rising from 20.3% in patients aged 20-49 years to 56.7% in those aged 80-89 years (table 1) . These findings are consistent with those of previous studies. 9, 15 It has been postulated that this may be attributable, in part, to less-aggressive management of SAH in elderly patients, 16 but there is limited evidence to support this. Similarly, 30-day case fatality for ICH also increased steeply with age, rising from 29.7% in patients aged 20-49 years to 54.6% in those aged 80-89 years (table 1) .
There was a decline in 30-day case-fatality rates for both ICH and SAH over the study period, with a reduction from 53.1% to 35.8% for ICH and from 33.3% to 24.7% for SAH between 2000-2001 and 2006-2008. This decrease coincides with the introduction of improved investigative, diagnostic, and management strategies for stroke. 17 These include the introduction of bedside neuromonitoring 18, 19 and the use of endovascular embolization to treat SAH in the United Kingdom, 20,21 both of which may have contributed to the observed reduction in 30-day case fatality.
A greater number of patients with SAH have been reported to die immediately or never recover from the initial bleed than individuals who have other types of stroke 22 ; consequently, fewer patients with SAH can benefit from the improved medical or surgical treatment regimens described above. This may account for the reduction in the number of case fatalities over time being smaller for SAH than for ICH. In addition, delays in gaining access to specialized acute stroke services and in obtaining timely scans, and consequent delays in diagnoses, for patients in the United Kingdom were found by the National Audit Office in 2005 23 ; it is therefore possible that the decline in the number of short-term case fatalities observed is the result of improvements in case ascertainment during the study period, leading to the diagnosis of milder forms of ICH with a better prognosis that would have previously gone undetected or been misclassified as ischemic stroke. 17 This scenario seems less likely for SAH, where a population-based study in the United Kingdom reported that improvements in SAH outcome could not be attributed to differences in SAH severity over time. 24 Existing data describing temporal trends in case fatality for hemorrhagic stroke are limited and conflicting, and comparison is hindered by the use of different time periods in studies. Similar to the findings presented here, a substantial reduction in 30-day case fatality following incident SAH was reported in a UK cohort of patients. 9 However, in an update to a previous meta-analysis, including only population-based prospective studies, 30-day case fatality for SAH was not observed to decline over the period 1972-2003 after adjustment for age and sex. 2 This might be attributable to the considerable heterogeneity in case findings and diagnostic approaches when the studies were combined. Furthermore, the 30-day case fatality reported for ICH in a previous study did not decrease between 1980 and 2006. 3 Such findings are in contrast to those presented here, where a decline in 30-day case fatality for both ICH and SAH was observed over the study period.
In the current study, patients who survived the initial 30 days after an ICH or SAH had a significantly increased risk of death compared with the control population both during the first year of follow-up and 1 year after the index event; this was observed across all age groups and was greatest for younger patients who had survived an ICH. In these patients (aged 20-49 years), the excess risk of death was almost 15-fold higher than that of the control population ( figure 3) . Overall, the risk of death in survivors of ICH was 2-fold that of individuals free from hemorrhagic stroke even 1 year after the event.
THIN is a useful data source enabling the analysis of a large number of samples that are representative of the UK primary-care population. Controls were sampled in THIN using the same source population where cases of ICH and SAH were ascertained. This control series was found to have similar survival rates compared with age-and sex-matched mortality data for England and Wales (table e-7) . 25 Thus, the use of THIN is a major strength of this study.
A limitation of all observational studies is the potential for inclusion of possible confounding variables. In this study, a multivariate analysis, adjusted for several relevant covariates and demographic factors, was used to control for this, although some unidentified minor confounding factors may still remain. It is also possible that some patients may have been misclassified as having a Table 2 Total number of individuals followed for each cohort and the number of deaths during follow-up Hazard ratios (HRs) with 95% confidence intervals (CIs) for intracerebral hemorrhage and subarachnoid hemorrhage. Control was used as the baseline category and adjusted estimates were obtained using a Cox proportional hazards model. hemorrhagic stroke; however, the method of detecting cases has been previously validated and showed an overall confirmation rate of correct classification of 82%. 11 Another potential source of error in the current study was the exclusion of patients who had not had a recorded visit to a PCP in the 2 years before entering the study. This may have led to an underestimation of the occurrence of hemorrhagic stroke; however, the incidences of ICH and SAH observed here are in line with those reported in the Oxford Vascular Study, 26 which used a method that should have captured all cases occurring in their catchment area. This suggests that the impact of excluding these individuals from the current study cohort was limited.
This large population-based study examined shortterm case fatality and long-term mortality in patients diagnosed with ICH and SAH between 2000 and 2008 in the United Kingdom. Our findings show that patients younger than 50 years are more likely to die after ICH compared with SAH. Furthermore, patients who survive the initial ICH or SAH episode continue to have an increased risk of death compared with individuals from an age-and sex-matched reference population.
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